Description: Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
Home Page: www.pharmamar.com
Avenida de los Reyes, 1
Madrid,
28770
Spain
Phone:
34 91 846 60 00
Officers
| Name | Title |
|---|---|
| Mr. Jose Maria Fernandez Sousa-Faro | Founder, Exec. Chairman, CEO & Pres |
| Mr. Pedro Francisco Fernandez Puentes | Exec. Vice-Chairman |
| Mr. Juan Carlos-Torres Carretero | Founder |
| Ms. María Luisa de Francia Caballero | Chief Financial Officer |
| Ms. Elena Calleja Crespo | Director of Fin. & Admin. |
| Mr. José Luis Moreno Martinez-Losa | Director of Capital Markets & Investor Relations |
| Mr. Juan Gomez Pulido | Gen. Counsel & Sec. of the Board of Directors |
| Ms. Sandra Llamera Sanchez | Global Compliance Head |
| Ms. Lara Vadillo | Communication Director |
| Mr. Juan Nogues | Director of International Marketing & Sales |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 13.1509 |
| Price-to-Book MRQ: | 5.5305 |
| Price-to-Sales TTM: | 5.4032 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 477 |